ZP1480 (AP214)



ZP1480 (AP214)

ZP1480 (AP214) is a first-in-class, peptide targeting melanocortin receptors modified with Zealand Pharma’s SIP®-technology for the treatment of cardiovascular diseases associated with ischemia and inflammation. ZP1480 is partnered with Action Pharma who is developing the drug for in-hospital, intravenous treatment of post-surgical Acute Kidney Injury (AKI) associated with cardiac surgery

In September 2011, Action Pharma announced positive results from a clinial Phase IIb study of ZP1480 in 77 patients undergoing major cardiac surgery with cardiopulmonary bypass who are at increased risk of developing acute kidney injury. The results showed that ZP1480 reduces kidney injury and improves long-term (90 days) outcomes on a composite end point (death, dialyses and kidney function) and that the compound is safe and well-tolerated compared to placebo.

The Phase IIb trial is a randomized, multi-center (3 in Denmark and 5 in the US), double-blind, placebo-controlled study evaluating the effect and safety of two dose levels of ZP1480 administered during surgery and early in the postoperative period. The results validate and expand on previous positive safety and efficacy data from a Phase IIa trial in 42 patients undergoing cardiac surgery.

Links to Action Pharma’s announcement of the Phase IIb results:. http://www.actionpharma.com/index.dsp?page=76.

Action Pharma plan to present the Phase IIb results at the American Society of Nephrology, November 8-13 in Philadelphia, PA, US

To top of page

Tip a friend

Fill in the form below to tip a friend about this page.






Subscribe

When this page is updated you will be updated by e-mail.